REVIEW
Nobel Med 2024; 20(2): 77-84

LIABILITY OF THE PHARMACEUTICAL MANUFACTURER ACCORDING TO ACT NO. 7223

Burcu G. Özcan Büyüktanır
ABSTRACT
The liability of the pharmaceutical manufacturer refers to the compensation by the pharmaceutical manufacturer for the damage caused to the property or personal assets of the person using the pharmaceutical due to the manufacturing defect in the pharmaceutical. There is no contractual relationship between the pharmaceutical manufacturer and the person using the pharmaceutical. The legal basis of this non-contractual liability is the Act on Product Safety and Technical Regulations (Act. No. 7223). Since the product refers to "any substance, preparation or objects" according to Article 3 of the Act., pharmaceuticals are also included within this scope. As well as the production and placing on the market are prerequisites for the liability to arise within the scope of Act., in addition to these; the pharmaceutical must be defective, damage must arise due

to the use of the pharmaceutical, there must be a causal link between the use of the pharmaceutical and the damage caused, and there must not be one of the exculpatory evidence regulated in the law. The manufacturing defect that causes the pharmaceutical to be unsafe could be like manufacturing / composition defect, fabrication defect, stimulation defect, development defect, or observation defect. The damage caused by the use of the pharmaceutical may be pecuniary or non-pecuniary. The pharmaceutical manufacturer is obliged to compensate for the damage caused by the pharmaceutical if these conditions are met. In addition, the pharmaceutical manufacturer cannot make a non-liability agreement that eliminates its liability for the damage. The period of limitations for the liability of the pharmaceutical manufacturer is regulated as three years from the date the injured party learns about the damage and the indemnity obligor and in any case ten years from the date of the damage.

LIABILITY OF THE PHARMACEUTICAL MANUFACTURER ACCORDING TO ACT NO. 7223

77-84

Burcu G. Özcan Büyüktanır

REVIEW Nobel Med 2024; 20(2): 77-84

PLASMA COENZYME Q10 LEVELS OF INDIVIDUALS WITH NEWLY DIAGNOSED TYPE 2 DIABETES AND DIABETES INDIVIDUALS WITH ADVANCED MICROALBUMINURIA: A COMPARATIVE STUDY

85-92

Osman Yıldırım, Birsen Demirel, Erdal Gündoğan, Hande Seven Avuk

RESEARCH ARTICLE Nobel Med 2024; 20(2): 85-92

IS THE EQ-5D-5L A RELIABLE INSTRUMENT IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFT SURGERY?

93-98

Zeliha Özdemir Köken, Hafize Savaş, Rana Elçin Sezer Ceren, Sevilay Şenol Çelik, Göktan Aşkın

RESEARCH ARTICLE Nobel Med 2024; 20(2): 93-98

ONLINE COGNITIVE BEHAVIORAL STRESS MANAGEMENT PROGRAM FOR BREAST CANCER PATIENTS

99-111

Esra Savaş, Merve Keleş, Özlem Tin

RESEARCH ARTICLE Nobel Med 2024; 20(2): 99-111

EVALUATION OF THE PERFORMANCE OF MACHINE LEARNING IN CLASSIFICATION OF IMAGES WITH OR WITHOUT MISSING TEETH IN PANORAMIC RADIOGRAPHS

112-118

Kübra Törenek Ağırman, Kübra Başaran Aslan

RESEARCH ARTICLE Nobel Med 2024; 20(2): 112-118

EFFECTS OF THE ANTIEPILEPTIC DRUGS CARBAMAZEPINE AND LEVETIRACETAM ON BONE HEALING IN RAT FRACTURE MODEL

119-127

Mesut Tıkman, Evrim Duman

RESEARCH ARTICLE Nobel Med 2024; 20(2): 119-127

FACTORS AFFECTING CERVICAL CANCER SCREENING BEHAVIOR IN WOMEN AGED 30-65 YEARS IN A DISTRICT IN ISTANBUL

128-134

Nefise Şeker, Halim İşsever

RESEARCH ARTICLE Nobel Med 2024; 20(2): 128-134

A CLASTOGENICITY STUDY WITH MITOMYCIN-C IN APLASTIC ANEMIA: DISTINGUISHING FANCONI ANEMIA

135-140

Gülçin Bağatir, Şükrü Öztürk, Ayşe Gül Bayrak Tokaç, Kıvanç Çefle, Aysegül Ünüvar, Zeynep Karakaş, Ayşe Palanduz, Şükrü Palanduz

RESEARCH ARTICLE Nobel Med 2024; 20(2): 135-140

DR. REFİK SAYDAM (1882-1942)

141-146

Turhan ADA

A PORTRAIT Nobel Med 2024; 20(2): 141-146

LIVER AND SYSTEMIC DISEASES

05-09

Sebati Özdemir

REVIEW Nobel Med 2013; 9(2): 5-9

AGING KIDNEY: SENESCENCE OR DISEASE?

10-14

Meltem Gürsu, Rümeyza Kazancıoğlu, Savaş Öztürk

REVIEW Nobel Med 2013; 9(2): 10-14

IMPORTANCE OF HOLOTRANSCOBALAMIN (HOLOTC) MEASUREMENTS IN EARLY DIAGNOSIS OF COBALAMIN DEFICIENCY, ESPECIALLY IN PATIENTS WITH BORDERLINE VITAMIN B12 CONCENTRATIONS

15-20

Faruk Sönmezışık, Esma Sürmen Gür, Burak Asıltaş

RESEARCH ARTICLE Nobel Med 2013; 9(2): 15-20

EVALUATION OF PHYSICAL GROWTH IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER

21-25

Celalettin Koşan, Oğuzhan Sepetçigil, Atilla Çayır, Avni Kaya, Behzat Özkan

RESEARCH ARTICLE Nobel Med 2013; 9(2): 21-25

COMPARISON OF RISK INDEXES USED IN DETERMINING THE POSTOPERATIVE RESPIRATORY INSUFFICIENCY RISK

26-31

Gülsüm Kavalcı, Cavidan Arar, Alkın Çolak, Nesrin Turan, Cemil Kavalcı

RESEARCH ARTICLE Nobel Med 2013; 9(2): 26-31

THE EVALUATION OF PRENATAL AND ENVIROMENTAL RISK FACTORS IN CHILDREN WITH ASTHMA, ALLERGIC RHINITIS AND BRONCHIAL ASTHMA ABSTRACT

32-37

Mehmet İbrahim Turan, Müferet Ergüven, Mehmet Özdemir

RESEARCH ARTICLE Nobel Med 2013; 9(2): 32-37

REOPERATIONS AND MORBIDITY IN THYROID SURGERY

38-42

Serkan Teksöz, Murat Özcan, Aytül Sargan, Yusuf Bukey, Recep Özgültekin, Ateş Özyeğin

RESEARCH ARTICLE Nobel Med 2013; 9(2): 38-42

EFFECTS OF RAMADAN FASTING ON BLOOD PRESSURE CONTROL, LIPID PROFILE, BRAIN NATRIURETIC PEPTIDE, RENAL FUNCTIONS AND ELECTROLYTE LEVELS IN HYPERTENSIVE PATIENTS TAKING COMBINATION THERAPY

43-46

İbrahim Faruk Aktürk, İsmail Bıyık, Cüneyt Koşaş, Ahmet Arif Yalçın, Mehmet Ertürk, Fatih Uzun

RESEARCH ARTICLE Nobel Med 2013; 9(2): 43-46

MANAGEMENT OF A LARGE OUTBREAK CAUSED BY NOROVIRUS AND CAMPYLOBACTER JEJUNI OCCURRED IN A RURAL AREA IN TURKEY

47-51

İbak Gönen

RESEARCH ARTICLE Nobel Med 2013; 9(2): 47-51

FREQUENT CD99 AND FLI-1 EXPRESSIONS IN DIFFUSE LARGE B-CELL LYMPHOMA AND THEIR ASSOCIATION WITH PROLIFERATIVE AND APOPTOTIC RATES

52-56

Ufuk Berber, İsmail Yılmaz, Tolga Tuncel, Zafer Küçükodacı Aptullah Haholu

RESEARCH ARTICLE Nobel Med 2013; 9(2): 52-56
  • Pubmed Style
    Burcu G. Özcan Büyüktanır. [İLAÇ ÜRETİCİSİNİN 7223 SAYILI ÜRÜN GÜVENLİĞİ VE TEKNİK DÜZENLEMELER KANUNUNA GÖRE HUKUKİ SORUMLULUĞU]. Nobel Med 2024; 20(2): 77-84, Turkish.
  • Web Style
    Burcu G. Özcan Büyüktanır. [İLAÇ ÜRETİCİSİNİN 7223 SAYILI ÜRÜN GÜVENLİĞİ VE TEKNİK DÜZENLEMELER KANUNUNA GÖRE HUKUKİ SORUMLULUĞU]. www.nobelmedicus.com/en/Article.aspx?m=1716 [Access: Mayıs 24, 2021], Turkish.
  • AMA (American Medical Association) Style
    Burcu G. Özcan Büyüktanır. [İLAÇ ÜRETİCİSİNİN 7223 SAYILI ÜRÜN GÜVENLİĞİ VE TEKNİK DÜZENLEMELER KANUNUNA GÖRE HUKUKİ SORUMLULUĞU]. Nobel Med 2024; 20(2): 77-84, Turkish.
  • Vancouver/ICMJE Style
    Burcu G. Özcan Büyüktanır. [İLAÇ ÜRETİCİSİNİN 7223 SAYILI ÜRÜN GÜVENLİĞİ VE TEKNİK DÜZENLEMELER KANUNUNA GÖRE HUKUKİ SORUMLULUĞU]. Nobel Med (2024); 20(2): 77-84, [cited Mayıs 24, 2021], Turkish.
  • Harvard Style
    Burcu G. Özcan Büyüktanır. (2024) [İLAÇ ÜRETİCİSİNİN 7223 SAYILI ÜRÜN GÜVENLİĞİ VE TEKNİK DÜZENLEMELER KANUNUNA GÖRE HUKUKİ SORUMLULUĞU]. Nobel Med, 20(2): 77-84, Turkish.